Statin nocebo effects have been demonstrated in numerous randomized, double-blind, placebo-controlled and active-controlled trials. Emerging evidence suggests that brain pathways might mediate statin nocebo hyperalgesia. Evidence-based pain-management approaches can be used to manage nocebo symptoms that occur during statin therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bradley, C. et al. Patient reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J. Am. Heart Assoc. 8, e011765 (2019).
Ganga, H. V., Slim, H. B. & Thompson, P. D. A systematic review of statin-induced muscle problems in clinical trials. Am. Heart J. 168, 6–15 (2014).
Moriarty, P. M. et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 9, 758–769 (2015).
Wood, F. A. et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2031173 (2020).
Robinson, J. G. New insights into managing symptoms during statin therapy. Prog. Cardiovasc. Dis. 62, 390–394 (2019).
Tinnermann, A., Geuter, S., Sprenger, C., Finsterbusch, J. & Büchel, C. Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. Science 358, 105–108 (2017).
Navar, A. M. et al. Prevalence and management of symptoms associated with statin therapy in community practice. insights from the PALM (Patient and Provider Assessment of Lipid Management) registry. Circ. Cardiovasc. Qual. Outcomes 11, e004249 (2018).
Singh Ospina, N. et al. Eliciting the patient’s agenda- secondary analysis of recorded clinical encounters. J. Gen. Intern. Med. 34, 36–40 (2019).
Navarese, E. P. et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 319, 1566–1579 (2018).
Zhang, H. et al. Discontinuation of statins in routine care settingsa cohort study. Ann. Intern. Med. 158, 526–534 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.G.R. has received research grants to the Institution from Acasti, Amarin, Amgen, Astra-Zeneca, Eli Lilly, Esperion, Medicines Company, Merck, Novartis, Novo-Nordisk, Regeneron and Sanofi, and consultant fees from COR2ED, Getz Pharma and Medicines Company.
Rights and permissions
About this article
Cite this article
Robinson, J.G. The neuropsychology of statin intolerance. Nat Rev Cardiol 18, 153–154 (2021). https://doi.org/10.1038/s41569-020-00502-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-020-00502-3
